Sartorius Stedim Biotech launches the innovative ambr 250 modular bioreactor system

New expandable benchtop workstation with unique single-use bioreactor design offers a simple approach to process development for fermentation and cell culture

Sartorius Stedim Biotech (SSB) has introduced the ambr 250 modular, an innovative benchtop bioreactor system for parallel fermentation or cell culture applications.

The system combines a unique single-use bioreactor vessel and an expandable system design to offer bioprocess scientists access to advanced benchtop bioreactor technology for process development.

The new ambr 250 modular system consists of a workstation with 2, 4, 6 or 8 single-use bioreactors, with a working volume range of 100–250mL. These mini bioreactors, based on the same stirred tank bioreactors in the well-established ambr 250 high throughput system, contain impellers suitable for fermentation or cell culture and show excellent scale up to larger bioreactors.

They are also fully integrated with liquid reservoirs and syringe pumps, allowing rapid experimental set-up and turnaround, significantly increasing lab efficiency.

The system brings simplicity to the lab bench. By following three easy steps, a bioreactor and all the required accessories can be connected in just a couple of minutes. Once installed, the bioreactor has all the required process services for parameter control, including pH, DO, temperature or agitation.

Additionally, feeds can now be delivered with high accuracy from the reagent reservoirs via the syringe pumps into the bioreactor. One control unit is capable of controlling up to eight bioreactor stations independently via an easy-to-use touchscreen user interface.

Mwai Ngibuini, Product Manager at SSB, states: ‘Our new ambr 250 modular solution provides an excellent single-use platform that enables rapid process development and optimisation for scale-up to larger bioreactors such as BIOSTAT pilot- and manufacturing-scale bioreactors. Utilising this single-use workflow will allow bioprocess scientists to improve productivity in their scalable bioprocess development and reduce their time lines, ensuring that the production of industrial enzymes, biologics and vaccines is more cost-efficient.’